Nouscom Revenue and Competitors
Estimated Revenue & Valuation
- Nouscom's estimated annual revenue is currently $8.8M per year.
- Nouscom's estimated revenue per employee is $155,000
Employee Data
- Nouscom has 57 Employees.
- Nouscom grew their employee count by 12% last year.
Nouscom's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP Finance | Reveal Email/Phone |
Nouscom Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7.7M | 61 | 20% | N/A | N/A |
What Is Nouscom?
Nouscom is a private oncology company developing next generation immunotherapies. Nouscom's proprietary technology platform, Exovax, harnesses the full power of immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators. Nouscom is led by an experienced management team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos (acquired by GSK), and are veterans in the field of genetic vaccines. Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors: 5AM, Abingworth, LSP (Life Sciences Partners) and Versant Ventures. For more information on Nouscom, please visit the company's website at www.nouscom.com
keywords:N/A
N/A
Total Funding
57
Number of Employees
$8.8M
Revenue (est)
12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Nouscom News
Avidea Technologies, Agenus, Roche, Nouscom, Genocea Biosciences, Gritstone Oncology, Gilead Sciences, BioNTech, ISA Pharmaceutical,...
Nouscom's Off-the-Shelf Cancer Vaccine. Switzerland's Nouscom presented encouraging new translational data from its ongoing Phase I study of...
Nouscom is a clinical stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer vaccines. Nouscom's...